Project

Pathogenesis and treatment of canine thyroid tumors (CTT)

Duration
01 May 2010 → 28 February 2015
Funding
Regional and community funding: Special Research Fund
Research disciplines
  • Natural sciences
    • Animal biology
  • Medical and health sciences
    • Endocrinology and metabolic diseases
    • Medical imaging and therapy
    • Endocrinology and metabolic diseases
    • Medical imaging and therapy
    • Endocrinology and metabolic diseases
    • Medical imaging and therapy
  • Agricultural and food sciences
    • Veterinary medicine
    • Other veterinary sciences
    • Other agricultural, veterinary and food sciences
Keywords
rhTSH radioiodine thyroid tyrosine kinase inhibitor cyclooxygenase-2 inhibitor
 
Project description

64 dogs with CTT are included in three clinical trials. Firstly, we will determine the effectiveness of cyclooxygenase-2 inhibitor (Piroxicam) and tyrosine kinase inhibitor (Toceranib Phosphate) in CTT treatment. Secondly, we will determine the best dosage, route and timing of rhTSH (recombinant-human-thyroid-stimulating-hormone) for radioiodine-131 treatment optimization. Thirdly, we will evaluate the effectiveness of rhTSH in the radioiodine-131 treatment of CTT.